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Neurobiology of Disease
Neuronal-Targeted TFEB Accelerates Lysosomal
Degradation of APP, Reducing A Generation and Amyloid
Plaque Pathogenesis
Qingli Xiao,1 Ping Yan,1 Xiucui Ma,2,4Haiyan Liu,2,4 Ronaldo Perez,1 Alec Zhu,1 Ernesto Gonzales,1
XDanielle L. Tripoli,1 XLeah Czerniewski,1 Andrea Ballabio,5 John R. Cirrito,1 XAbhinav Diwan,2,3,4* and
X Jin-Moo Lee1*
1Department of Neurology and the Hope Center for Neurological Disorders, 2Center for Cardiovascular Research in Department of Medicine, and
3Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri 63110, 4John Cochran VAMedical Center, St.
Louis, Missouri 63108, and 5Telethon Institute of Genetics and Medicine, Pozzuoli, Naples, Italy 80078
In AD, an imbalance between A production and removal drives elevated brain A levels and eventual amyloid plaque deposition. APP
undergoesnonamyloidogenicprocessingvia-cleavageat theplasmamembrane, amyloidogenic- and-cleavagewithin endosomes to
generate A, or lysosomal degradation in neurons. Considering multiple reports implicating impaired lysosome function as a driver of
increased amyloidogenic processing of APP, we explored the efficacy of targeting transcription factor EB (TFEB), a master regulator of
lysosomal pathways, to reduce A levels. CMV promoter-driven TFEB, transduced via stereotactic hippocampal injections of adeno-
associated virus particles in APP/PS1mice, localized primarily to neuronal nuclei and upregulated lysosome biogenesis. This resulted in
reduction of APP protein, the and C-terminal APP fragments (CTFs), and in the steady-state A levels in the brain interstitial fluid.
In agedmice, total A levels and amyloid plaque loadwere selectively reduced in theTFEB-transducedhippocampi. TFEB transfection in
N2a cells stably expressing APP695, stimulated lysosome biogenesis, reduced steady-state levels of APP and - and -CTFs, and atten-
uatedA generation by accelerating flux through the endosome-lysosomepathway. Cycloheximide chase assays revealed a shortening of
APP half-life with exogenous TFEB expression, which was prevented by concomitant inhibition of lysosomal acidification. These data
indicate that TFEB enhances flux through lysosomal degradative pathways to induce APP degradation and reduce A generation.
Activation of TFEB in neurons is an effective strategy to attenuate A generation and attenuate amyloid plaque deposition in AD.
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Introduction
In AD, increased generation of the A peptide in neurons syner-
gizes with impairedA removal from the interstitial fluid (ISF) in
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Significance Statement
A key driver for AD pathogenesis is the net balance between production and clearance of A, the major component of amyloid
plaques. Here we demonstrate that lysosomal degradation of holo-APP influences A production by limiting the availability of
APP for amyloidogenic processing. Using viral gene transfer of transcription factor EB (TFEB), a master regulator of lysosome
biogenesis in neurons of APP/PS1mice, steady-state levels of APPwere reduced, resulting in decreased interstitial fluid A levels
and attenuated amyloid deposits. These effects were caused by accelerated lysosomal degradation of endocytosed APP, reflected
by reduced APP half-life and steady-state levels in TFEB-expressing cells, with resultant decrease in A production and release.
Additional studies are needed to explore the therapeutic potential of this approach.
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driving extracellular amyloid plaque formation (Haass et al.,
2012) and the resultant neuropathogenesis (Bloom, 2014). After
synthesis in the endoplasmic reticulum, APP is trafficked from
the Golgi to the plasma membrane, where it is cleaved by
-secretases within the A peptide fragment region, in a manner
that precludes A generation (i.e., nonamyloidogenic or-cleav-
age; Rajendran and Annaert, 2012). Alternately, APP is endocy-
tosed, and sequentially cleaved by a -secretase (BACE1) and
then the -secretase complex (comprised of presenilins, nicas-
trin, APH-1, and PEN2) within endosomes, to generate A pep-
tides (amyloidogenic cleavage; Rajendran and Annaert, 2012).
Accumulating evidence suggests that dysregulation of endocyto-
sis (Harold et al., 2009; Ginsberg et al., 2010) with accumulation
of large endosomes within neurons, as observed in preclinical
stages of AD pathology (Cataldo et al., 2000) and in neurons
transdifferentiated from fibroblasts of patients with AD (Israel et
al., 2012), increases the proclivity for amyloidogenic processing
of APP.
Endocytosed APP can be sorted back to the Golgi (Morel et
al., 2013) or trafficked to lysosomes along with other endo-
somal cargo (The´ry et al., 2002). Indeed, a large fraction of
full-length APP is degraded within lysosomes (Caporaso et al.,
1992, 1994; Golde et al., 1992; Haass et al., 1992). Experimen-
tal inhibition of lysosome function markedly prolongs APP
half-life (Caporaso et al., 1992) and impairs endocytotic flux
with accumulation of enlarged vesicles in dystrophic neurites
mimicking AD pathology (Lee et al., 2011), with increased
BACE1 (Chia et al., 2013) and -C-terminal fragment (Golde
et al., 1992; Sannerud et al., 2011) resulting in markedly in-
creased A generation. Relevant to this discussion is that im-
paired lysosomal function is observed with aging (Kato et al.,
1998; Cuervo and Dice, 2000; Wolfe et al., 2013) and with loss
of presenilins (due tomutations causing familial AD; Lee et al.,
2010; Neely et al., 2011; Coen et al., 2012), and is suspected
with polymorphisms in genes coding for lysosomal proteins,
which confer increased risk for sporadic AD, including phos-
pholipase D3 (Cruchaga et al., 2014), cystatin C (Hua et al.,
2012), and Cathepsin D (Schuur et al., 2011). Also, levels of
APP, its -CTF, and A are increased in mouse models of
lysosome storage disorders, namely, Neimann-Pick disease
(Kodam et al., 2010), mucolipidoses (Keilani et al., 2012), and
sphingolipidoses (Tamboli et al., 2011). These observations
incriminate lysosomal dysfunction as the common cellular
mechanism in provoking increased A generation and im-
paired A removal (Funk and Kuret, 2012; Peric and Annaert,
2015).
As a therapeutic strategy to address lysosomal insufficiency in
astrocytes, we previously evaluated activation of transcription
factor EB (TFEB), a master inducer of lysosomal degradative
pathways (Settembre et al., 2013a), and demonstrated that astro-
cytic TFEB expression stimulates A uptake and its lysosomal
degradation to reduce ISF A (Xiao et al., 2014). In this study, we
evaluated the efficacy of neuronal TFEB activation in enhancing
lysosomal degradation of APP to reduce A levels and attenuate
amyloid plaque pathogenesis.
Materials andMethods
Studies in animal models. APP/PS1 transgenic mice (B6C3-Tg (APPswe/
PS1E9)85Dbo/Mmjax) of either sex were obtained from The Jackson
Laboratory (Jankowsky et al., 2004) and injected with AAV8 viral parti-
cles (generated by theHopeCenterViral Core atWashingtonUniversity)
driving expression of TFEB (AAV8-CMV-FLAG-TFEB) or GFP as con-
trol (AAV8-CMV-GFP), each with 2 l of 1.5 1012 viral genomes per
milliliter into bilateral hippocampi at 6 months of age, as described pre-
viously (Xiao et al., 2012).Wild-typemice of either sex were also injected
with AAV8-CMV-FLAG-TFEB or AAV8-CMV-GFP at 4 months of age
to assess the effect of TFEB transduction on endogenous APP processing
after 4 months. Before injection, AAV particles were subjected to two
rounds of cesium chloride gradient purification and titers were quanti-
fied by assessment of viral genomes. For plaque load studies, TFEB or
control-transduced APP/PS1 mice (six males and eight females per
group) were killed 4 months later. One hemisphere was fixed and
coronal sections (50 m) were cut for histological analysis (X-34
staining and HJ3.4 immunostaining). The other hemisphere was snap
frozen on dry ice and stored at 80°C for biochemical analysis
(ELISA and immunoblotting). To assess the abundance of A species
in predepositing mice, the abovementioned AAV viral vectors were
injected into the hippocampi of APP/PS1 mice of either sex at 2
months of age and the animals were killed 1 month later. All animal
care and surgical procedures were approved by the Animal Studies
Committee of Washington University School of Medicine in accor-
dance with guidelines of the NIH.
In vivo microdialysis. AAV particles driving expression of TFEB
(AAV8-CMV-FLAG-TFEB) or GFP as control (AAV8-CMV-GFP)
were transduced by stereotactically guided injection in the hippocam-
pus of 2-month-old APP/PS1 transgenic mice of either sex followed
by in vivo microdialysis, 1 month later, as previously described (Cir-
rito et al., 2003, 2011). All studies were initiated at the same time of
day. Briefly, a guide cannula (BR-style; Bioanalytical Systems) was
implanted and cemented with the tip at coordinates: bregma 3.1
mm, midline 2.5 mm, 1.2 mm below dura at a 12° angle. A 2 mm
microdialysis probe was then inserted into the hippocampus that
contained a 38 kDaMWCO semipermeable membrane (Bioanalytical
Systems) allowing molecules smaller than this cutoff to diffuse into
the probe. A capable of entering the probe is dubbed “exchangeable
A” (eA; Cirrito et al., 2003). The probe was flushed with 0.15%
bovine serum albumin (Sigma) in an artificial CSF perfusion buffer at
a constant rate (1.0 l/min). The effluate was collected into a refrig-
erated fraction collector and assayed by sandwich ELISA for Ax-40
peptides at the end of each experiment. During microdialysis, animals
were housed in specially designed cages to permit free movement and
ad libitum food and water while ISF Awas sampled. Baseline levels of
ISF A were sampled every 90 min between hours 9 and 16 (after the
microdialysis probe is inserted) and averaged to determine the “base-
line ISF A level” in each mouse. Absolute in vivo concentration of
ISF eA for each mouse was determined by correcting for the 20.8%
recovery (1.0 l/min) as obtained by the interpolated zero flow
method described previously (Menacherry et al., 1992; Cirrito et al.,
2003). At hour 16 (t  0), a -secretase inhibitor, Compound E (200
nM reverse microdialysis; synthesized by AsisChem), was adminis-
tered directly to the hippocampus by adding the drug to the microdi-
alysis perfusion buffer. ISF A was then sampled every 60 min for an
additional 8 h. This enabled measurement of the elimination half-life
of endogenous ISF A in vivo as described previously (Cirrito et al.,
2003).
Immunohistochemistry. Frozen brain sections were incubated in 0.3%
H2O2 in TBS for 10 min and blocked with 3% dry milk in TBS-X (0.25%
TritonX-100 inTBS) for 1 h, followedby incubationwithHJ3.4 antibody
(anti-A-1-13; Roh et al., 2012) overnight. Thereafter solution A from
Vectastain ABC kit (1:400) was applied for 1 h, followed by 0.025%DAB
in 0.25% NiCl2 and 0.05% H2O2 for 10–15 min. The slices were placed
on glass slides, dried overnight, dehydrated and mounted, and imaged
with confocal microscopy (Zeiss LSM).
X-34 plaque staining. Brain slices were mounted on SuperFrost Plus
slides, permeabilized with 0.25% Triton X-100 for 30 min, and stained
with X-34 (dissolved in 40% ethanol, 60%water, pH 10.0; a generous gift
from Robert Mach, Washington University, St. Louis, MO) for 20 min.
Thereafter the tissue was thoroughly rinsed in PBS and mounted with
Fluoromount mounting media.
Amyloid plaque quantification. Fifty micrometer thick brain sections
were collected every 300 ms from the rostral anterior commissure to
caudal hippocampus. For plaque imaging, sections were stained with
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X-34 or immunostained withHJ3.4 anti-A antibodies. High-resolution
digital images of the stained brain slices were obtained with the NanoZo-
omer Digital Scanner (Hamamatsu Photonics). The total area of plaque
coveragewasmeasured usingNIH ImageJ in the region of the hippocam-
pus or piriform cortex (devoid of viral transduction) and expressed as
percentage total area for each slice. Results from n  4 sections were
averaged to represent each animal.
Immunofluorescence. Paraffin-embedded brain sections were washed
with PBS and permeabilized with 0.3% Triton X-100 in PBS for 20 min
followed by blocking. For double labeling, a mixture of the following
antibodies was used: mouse anti-TFEB (MyBioSource, 1:100), rabbit
anti-NeuN (Abcam; 1:100), rabbit anti-GFAP (Sigma; 1:100), and rab-
bit anti-Iba1 (Wako Chemicals; 1:1000). A secondary antibody mixture
of Alexa Fluor 488-conjugated goat anti-mouse IgG and Alexa Fluor
594-conjugated goat anti-rabbit IgG (Invitrogen) was applied. Sections
were imaged by confocal microscopy (Zeiss LSM).
Neuronal counts. Stereological analysis for neuronal counts was per-
formed on sections stained with 0.05% cresyl violet solution, as previ-
ously described (Xiao et al., 2014). Briefly, cresyl violet-stained cells with
nuclei imaged within the inclusive zone of each dissector frame were
counted in four equally spaced sections (50 m apart) in the dorsal
hippocampus of strata pyramidale CA1 and CA3, using a computer-
based stereology system (Stereo Investigator; MicroBrightField) with the
optical fractionator (West et al., 1991).
In vitro studies. N2a cells stably expressing the human APP695
construct (N2a-APP695) were grown in DMEM/Opti-MEM (50:50)
supplemented with 5% FBS and 200 g/ml G418 and transfected with
FLAG-tagged murine TFEB or empty vector, as described previously
(Xiao et al., 2014). We observed 90% efficiency for transfection of
exogenous TFEB (or GFP as control) in these in vitro studies. For assess-
ment of APP half-life by cycloheximide chase assay, N2a-APP695 cells
transfected with TFEB (or control) were treated with 50g/ml cyclohex-
imide followed by preparation of cellular extracts at various time inter-
vals for immunoblotting for APP. To inhibit lysosome acidification and
function, studies were performed in the presence of bafilomycin A1 (100
nM), as previously described (Xiao et al., 2014). Studies with cell-surface
biotinylation to assess internalization of APP were performed as de-
scribed previously (Xiao et al., 2012). Briefly, cells cultured in 6-well
plates were washed with cold PBS and surface proteins were labeled with
the nonmembrane-permeant, cleavable biotin derivative, sulfo-NHS-
SS-biotin (1mg/ml in PBS). Cells were kept at 4°C for 30min in the dark
and gently rocked during the incubation period. The biotin reagent was
quenched by treating the cells with two 15min washes of 0.1 M glycine in
PBS. Cells were rinsed with PBS and lysed in RIPA buffer containing 50
mM Tris-HCl, pH 7.5; 150mMNaCl; 1% (v/v) Nonidet P-40; 0.5% (w/v)
deoxycholate; and 1 protease inhibitor mixture. Lysates were incu-
bated with Dynabeads MyOne Streptavidin T1 (Invitrogen) for 2 h in a
rotary mixer to isolate biotin-labeled proteins. A cohort of surface biotin-
labeled cells was incubated for 0, 1, 2, 3, 5, 7.5, 10, 20, and 30min at 37°C to
allow internalization, followed by rapid cooling on ice to stop endocytosis.
To cleave biotin exposed at the cell surface, these cells were incubated three
times for 20min at 4°Cwith 50mM2-mercaptoethanesulfonic acid (Sigma)
in50mMTris-HCl,pH8.7; 100mMNaCl; and2.5mMCaCl2.After thorough
rinsing with PBS containing 20mMHEPES, cells were lysed in RIPA buffer,
and internalized biotinylated proteins were immunoprecipitated with
streptavidin followedby immunoblotting forAPP(CT695; Invitrogen).Up-
take of biotin-labeled transferrin (T3915; Sigma) was assessed in parallel in
TFEB and vector-transfected cells to determine the effect of TFEB on
clathrin-mediated endocytosis. Immunofluorescence was performed on
C17.2 cells cotransfectedwithCer-APP-YFPandTFEBorcontrol vector and
incubated with LysoTracker Red (L7526; Invitrogen) to label the lysosome
compartment, and live cells were examined by confocal microscope (Zeiss
LSM).
A ELISA. A species in cell lysates and media from transfected N2a-
APP695 were detected by sandwich ELISA, as previously described (Xiao
et al., 2014). To detect total A in the hippocampus in 3-month-old
mice, dissected tissue was sequentially homogenized in PBS followed by
RIPA buffer to obtain detergent-soluble A at an age when plaques are
not observed (Yan et al., 2009), and samples were pooled for analysis. In
aged mice (10 months old, when plaques are abundant), hippocampal
tissues were sequentially homogenized in PBS followed by 5 M guanidine
in TBS, pH 8.0 (to extract fibrillar and membrane-bound A). For
ELISA assays, Ax-40 and Ax-42 peptides were captured with mouse
monoclonal-coating antibodies HJ2 (anti-A35-40) and HJ7.4 (anti-
A37-42) or HJ5.1 (anti-A13-28), respectively, as previously described
(Kim et al., 2009; Xiao et al., 2014). HJ5.1 (anti-A13-28), a biotinylated
antibody targeting the central domain, or HJ3.5 (anti-A1-13, provided
by Dr. David Holtzman, Washington University School of Medicine, St.
Louis, MO), which targets the N-terminal amino acids, was used as the
detecting antibody, followed by streptavidin-poly-HRP-40 (Fitzgerald
Industries). All ELISA assays were developed using Super Slow ELISA
TMB (Sigma) and absorbance read on a Bio-Tek Epoch plate reader at
650 nm. Standard curves were generated from synthetic human A1–40
or A1–42 peptides (American Peptide).
Quantitative PCR. Real-time PCR was performed as described previ-
ously (Ma et al., 2012). Briefly, total RNA was prepared from transfected
N2a-APP695 cells or AAV-transduced hippocampus using an RNA-easy
mini kit (Qiagen), and cDNA was synthesized with 1 g of total RNA
using the SuperScript III first-strand synthesis system (Invitrogen). One
microliter of cDNA template was mixed with 12.5l of 2 SYBR Green
PCRMaster Mix (Invitrogen) and subjected to quantitative PCR in trip-
licate under the following conditions: 50°C, 2 min; 95°C, 10 min; fol-
lowed by 40 cycles of 95°C, 15 s; 60°C, 1 min in the ABI7500 Fast
RealTime PCR system. The housekeeping gene GAPDH was also ampli-
fied in parallel as a reference for the quantification of transcripts. Primer
sequences used have been previously described (Xiao et al., 2014).
Immunoblotting. Protein samples were run on 4–12% Bis-Tris gels.
Blots were probed with the following antibodies: FLAG (Sigma; 1:1000),
TFEB (MyBioSource; 1:500), LAMP1 (Santa Cruz Biotechnology;
1:500), Cathepsin B (Abcam; 1:500), Cathepsin D (a generous gift from
Stuart Kornfeld, Washington University, St. Louis, MO; 1:2000), APP
CT695 (to detect both full-length APP and C-terminal fragments; Invit-
rogen; 1:500), 6E10 (to detect sAPP; Covance; 1:1000), Adam10 (Santa
Cruz Biotechnology; 1:100), Adam17 (Millipore; 1:1000), BACE1 (Cell
Signaling Technology; 1:1000), Psen1 (Santa Cruz Biotechnology;
1:200), nicastrin (Thermo Scientific; 1:1000), IDE (Abcam; 1:2000), ne-
prilysin (Millipore; 1:500), MMP2 (Abcam; 1:1000), MMP9 (Abcam;
1:1000), HRP-conjugated biotin (Cell Signaling Technology; 1:1000),
and actin (Sigma; 1:2000). Normalized band intensity was quantified
using ImageJ software.
Statistical analysis. All data are shown as Mean  SEM. Data were
analyzed by two-tailed Student’s t test for detecting significant differ-
ences between two groups. Differences among multiple groups were an-
alyzed by one-way and two-way ANOVA for one and two independent
variables, respectively, followed by post hocTukey’s test. Statistical signif-
icance was pegged at p 0.05 (*p 0.05 and **p 0.01).
Results
AAV-CMV-TFEB transduces TFEB specifically in neurons of
APP/PS1mice with upregulated lysosome abundance
Lysosomal dysfunction is speculated to play a central role in en-
hanced A generation in neurons (Lee et al., 2010; Neely et al.,
2011; Coen et al., 2012; Funk and Kuret, 2012; McBrayer and
Nixon, 2013; Wolfe et al., 2013) or its impaired clearance (Wyss-
Coray et al., 2003; Majumdar et al., 2011; Lee et al., 2012; Kane-
kiyo et al., 2013). In previous studies, we demonstrated that
targeting expression of TFEB, a master inducer of lysosomal bio-
genesis (Sardiello et al., 2009; Settembre et al., 2011, 2013b), spe-
cifically to astrocytes, stimulated lysosome biogenesis and
function resulting in accelerated A uptake and degradation
(Xiao et al., 2014). In the current study, we explored the hypoth-
esis that enhancing lysosomal biogenesis in neurons with exoge-
nous expression of TFEB will stimulate lysosomal degradation of
holo-APP to attenuate A production. Accordingly, we per-
formed stereotactically guided injections of AAV8 particles en-
coding a CMV promoter-driven construct to transduce TFEB
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(AAV8-CMV-FLAG-TFEB; and AAV8-
CMV-GFP as control) in the hippocam-
pus of 6-month-old APP/PS1 mice, at a
stage of early plaque deposition and
growth (Yan et al., 2009). Stereotactic
AAV injections consistently resulted in
widespread transduction in thehippocam-
pus (data not shown). As we observed pre-
viously (Xiao et al., 2012), the CMV
promoter-driven construct specifically re-
sulted inTFEB expression inneuronswith a
neuron-specific marker, NeuN, and not
in astrocytes or microglia (Fig. 1A). Im-
portantly, exogenous TFEB localized to
the neuronal nuclei (Fig. 1A) and hip-
pocampal extracts from AAV8-TFEB-
transduced mice demonstrate robust
overexpression with TFEB (11-fold in-
crease over control, p 0.01; N 3 per
group) with increased abundance of lys-
osomal proteins, LAMP1, and Cathep-
sin B and Cathepsin D (Fig. 1B,C), two
lysosomal proteases that have been im-
plicated in APP degradation (Higaki et
al., 1996; Mueller-Steiner et al., 2006).
Neuronal TFEB expression drives
reduced APP abundance, in vivo
APP695 is synthesized and processed pri-
marily in neurons, where its sequential
cleavage via the- and-secretases results
in generation of amyloidogenic A pep-
tides (Hartmann et al., 1997; Kamenetz et
al., 2003). Alternately, APP processing can
proceed via -secretases in a manner that
precludes A generation (Haass et al.,
2012). Studies have demonstrated that a
large fraction of full-length APP protein is
also degraded within lysosomes, which
may limit the pool of APP available for-,
-, and -cleavage (Caporaso et al., 1992,
1994; Golde et al., 1992). Given that TFEB drives upregulation of
the lysosomal machinery, we examined the effect of neuronal
TFEB expression on abundance of APP and its various cleavage
fragments. TFEB-transduced hippocampal extracts demon-
strated a 28%reduction inAPPprotein abundance, accompanied
by a matching 31 and 36% reduction in -CTF and -CTF (Fig.
2A,B). Given previous observations that amyloid pathogenesis is
accelerated in female mice (Callahan et al., 2001), we examined
the effects of TFEB transduction in male and female mice sepa-
rately. We observed comparable reductions in APP in the two
sexes (by 29% inmales vs 30% in females; data not shown). These
data show that the effect of neuronal TFEB expression on APP
abundance is independent of gender.
The reduction in APP abundance was not caused by a difference
in the transcript levels for the transgenically expressed human
APP695 protein (Fig. 2C) or in the expression of -secretases and
components of the- and-secretasemachinery between theTFEB
and control-transduced hippocampi (Fig. 2C–E). Importantly,
TFEB-transduced hippocampi did not demonstrate a difference in
neuronal counts comparedwith control (Fig. 2F), ruling out neuro-
nal toxicity as the underlying cause for these observations. Together
with the proportionately comparable reductions in various CTFs,
these data suggest that TFEB expression facilitates holo-APP degra-
dation via pathways that do not involve APP processing by
-cleavage or sequential - and -cleavage.
Neuronal TFEB expression reduces ISF A levels, in vivo
A peptides are released into the ISF and removed via cellular
uptake and degradation, extracellular proteolysis, or transport
across the blood–brain barrier. Consequently, the steady-state
level of A in the ISF is determined by the balance between its rate
of production and degradation. Considering that exogenous
TFEB expression results in a reduction in total APP levels with a
parallel reduction in abundance of its cleaved fragments (Fig.
2A,B), we hypothesized that TFEB transduction will attenuate
A production resulting in reduced A steady-state levels in the
ISF. Accordingly, we transduced 2-month-old APP/PS1 mice
with AAV8-CMV-FLAG-TFEB and control AAV8-CMV-GFP
viral particles and performed in vivomicrodialysis 1 month later
to determine whether neuronal TFEB expression impacts ISF A
at a time point before deposition of plaques (Yan et al., 2009) to
avoid a potential confounding influence from exchangeable
plaque-bound A pool. TFEB-transduced mice demonstrated a
57% reduction in steady-state ISF A levels compared with con-
Figure 1. AAV8-CMV-TFEB drives lysosome biogenesis in neurons. A, Representative confocal images demonstrating expres-
sion of TFEB (green) in various CNS cell typesmarked by the expression of NeuN (neurons; red, top), GFAP (astrocytes; red,middle),
and Iba-1 (microglia; red, bottom) in the hippocampus of APP/PS1mice injectedwith AAV8-CMV-FLAG-TFEB particles. The boxed
inserts (upper left corners) demonstratemagnified images of TFEB-expressing cells.B, C, Immunoblots (B) with quantification (C)
of lysosomal proteins in extracts from hippocampi transducedwith AAV8-CMV-FLAG-TFEB (TFEB) or AAV8-CMV-GFP (GFP).N 3
per group; **p 0.01.
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trols (Fig. 3A). After steady-state measures of ISF A were ob-
tained, a potent -secretase inhibitor, Compound E, was
administered to inhibit APP cleavage to A (Cirrito et al., 2011),
and ISF was sampled for an additional period of 8 h to determine
the elimination rate (half-life) of pre-existingA (Fig. 3A), which
was observed to follow first-order kinetics in both control and
TFEB-transduced mice (Fig. 3B). We observed a modest 24%
reduction in half-life of ISF A in CMV-TFEB-transduced hip-
pocampi, indicating that neuronal TFEB transduction also accel-
erates A removal from ISF (Fig. 3B). That steady-state ISF A
levels are reduced by 57%, but half-life is reduced by only 24%,
strongly suggests that TFEB has only a minor role in enhancing
ISF A clearance with the primary effect instead on reducing A
production. Indeed, previous studies have demonstrated that
neurons take up A via endocytosis andmacropinocytosis, and it
is conceivable that TFEB transduction stimulates A uptake in
neurons via the latter similar to our studies with astrocyte-
targeted TFEB expression (Xiao et al., 2014). Importantly, the
effect of exogenous TFEB on reduction in ISF A levels and A
half-life was comparable in both sexes (data not shown). We
also explored the possibility that TFEB transduction could
enhance extracellular degradation of A, but did not observe
any alteration in the transcript levels for known A-
metabolizing enzymes (MMP2, MMP9, IDE, or neprilysin) in
TFEB-transduced hippocampi (Fig. 3C). Analogously, the
protein abundance for these enzymes was unchanged (MMP2,
MMP9, and IDE) or modestly reduced (neprilysin; Fig. 3D,E),
suggesting that regulation of extracellular proteases is unlikely
to contribute to a reduction in ISF A levels with neuronal
TFEB transduction.
Importantly, total immunodetectable A levels were also
reduced in the hippocampal extracts from TFEB-transduced
mice at this early stage of amyloid pathogenesis, compared
with controls (Fig. 3F,G), confirming that the reduction in
steady-state levels of ISF A was not due to intracellular A
accumulation. Together with the reduction in APP abundance
and that of its various cleaved fragments (Fig. 2A,B), these
data point to a predominant effect of neuronal TFEB expres-
sion on attenuating A generation with a modest effect on
accelerating A removal as the primary driver of reduced
steady-state ISF A levels.
Neuronal TFEB expression reduces A levels and amyloid
plaques in APP/PS1 transgenic mice
ISF A levels correlate with amyloid plaque pathology (Bero et
al., 2011), supporting the hypothesis that A aggregates into am-
yloid plaques in a concentration-dependent manner, in vivo. In-
deed, studies from our laboratory as well as others have
demonstrated that strategies to reduce ISF A levels drive a re-
duction in amyloid plaque deposition (Cramer et al., 2012; She-
line et al., 2014; Xiao et al., 2014). Accordingly, we posited that
neuronal TFEB transduction will drive reduction in fibrillar A
aggregates and attenuate deposition of amyloid plaques in aging
APP/PS1 mice. To investigate this premise, we subjected TFEB-
transduced (and control) hippocampal tissue to sequential ho-
mogenization in PBS followed by guanidine to quantify A in
PBS-soluble and PBS-insoluble fractions. In addition, we per-
formed A immunohistochemistry and X-34 staining to assess
A and amyloid load, respectively. As shown (Fig. 4A–C), TFEB
transduction resulted in a 40 and 50% reduction in soluble A40
Figure2. Neuronal TFEB transduction results in reducedAPPabundance.A,B, Immunoblot (A)withquantitation (B) ofAPPand its- and-CTFs inAPP/PS1mousehippocampi transducedwith
AAV8-CMV-FLAG-TFEB (TFEB) or AAV8-CMV-GFP (GFP). N 6 per group (n 3 males and n 3 females); **p 0.01. Representative immunoblot is frommale mouse tissues. C, Expression of
transcripts coding for various components of the APP-processing machinery in hippocampal tissues transduced with AAV8-CMV-FLAG-TFEB (TFEB) or AAV8-CMV-GFP (GFP). N 5 per group. No
statistically significant differenceswerenoted for anyof the transcripts.D,E, Immunoblot (D) andquantitation (E) of APP-processingmachineryproteins inhippocampi transducedwith TFEB (orGFP
as control, as in A).N 3 per group. F, Neuronal counts in the CA1 and CA3 layers of the hippocampi fromAAV8-CMV-FLAG-TFEB (TFEB) and AAV8-CMV-GFP (GFP)-transduced APP/PS1mice.N
4 per group.
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and A42, and 36 and 35% reduction in insoluble A40 and
A42, respectively, comparedwith controls, by an ELISA assay to
differentially capture the two species by specific C-terminal anti-
bodies. To confirm these findings, we also used an alternate A
peptide capture and detection strategy using a combination of
antibodies targeting distinct epitopes at the central domain
(HJ5.1) andN terminus (HJ3.5), as previously described (Xiao et
al., 2014), and observed a 29 and 31% reduction in the soluble
and insoluble levels of all A species in TFEB-transduced hip-
pocampi (Fig. 4A–C). This suggests a uniform reduction in A
levels rather than a reduction in specific truncated fragmentswith
exogenous TFEB expression.
This was accompanied by a 35% reduction in X-34-stained
amyloid deposits (Fig. 4D,E) and a 40% reduction in A-
immunostained amyloid plaque load (Fig. 4G,H). Importantly,
as we have observed previously with astrocytic expression of ex-
ogenous TFEB (Xiao et al., 2014), the effect of neuronal TFEB
transduction on amyloid deposition was localized to the hip-
pocampus (see area outlined with dotted line in Fig. 4D and G
and quantitation in E and H), which was targeted for TFEB ex-
pression by stereotactic injection and not in the cortical areas that
are distant from the site of AAV transduction. It is interesting to
note that the degree of reduction in plaque load mirrored that of
the reduction inA levels (Fig. 4B,C) in the agedmice and that of
the reduction in ISF steady-state A (Fig. 3A,B) and hippocam-
pal A in the predepositing mice (Fig. 3F,G), attesting to a con-
sistent effect of TFEB on A generation throughout the various
stages of amyloid pathogenesis. It is also noteworthy that TFEB-
Figure 3. Neuronal TFEB transduction reduces ISF A levels, in vivo. A, Assessment of A levels by in vivo microdialysis in 3-month-old APP/PS1 mice transduced with AAV8-CMV-FLAG-TFEB
(TFEB) and AAV8-CMV-GFP (GFP) with serial hourly measurements. N 8mice in TFEB group, n 9mice in GFP group. At t 0, mice were continually administered Compound E directly to the
hippocampus (200 nM, reversemicrodialysis) followed by hourly sampling for A. Inset showsmean absolute in vivo “exchangeable” A (eAx-40) concentration averaged over a 9 h period before
drug administration; *p 0.05.B, Semilog plot of decline in percentage basal ISF A levels during administration of Compound E in animals inA. Inset shows A half-life in the two groups; *p
0.05. C–E, Transcript levels (C) and protein abundance [immunoblot (D)with quantitation (E)] for enzymes implicated in extracellular Ametabolism in hippocampal tissue fromAAV8-CMV-FLAG-
TFEB (TFEB) andAAV8-CMV-GFP (GFP)-transducedAPP/PS1mice.N5per group; **p0.01.F,G, A40andA42 levels indissectedhippocampal tissues fromAAV8-CMV-FLAG-TFEB (TFEB) and
AAV8-CMV-GFP (GFP)-transduced APP/PS1 mice at 3 months of age. Tissue was homogenized first in PBS (D) then in RIPA (E) quantified with ELISA assay. HJ2 and HJ7.4 antibodies were used for
capture A40 and A42, respectively, and HJ5.1 antibody was used for detection. N 6 mice per group; **p 0.01.
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transduction had a comparable effect on amyloid plaque load
reduction in either sex (Fig. 4F, I), as we have previously ob-
served (Xiao et al., 2014).These data suggest that TFEB
expression in neurons attenuates amyloid plaque deposition via
reducing A generation.
Neuronal TFEB transduction reduces APP and A levels in
wild-type mice
To exclude the possibility that TFEBprimarily affects the process-
ing of the mutant APP695 protein, which is co-overexpressed
with a familial AD risk conferring E9 mutant presenilin-1 pro-
tein in the APP/PS1 mice (Jankowsky et al., 2004), we examined
the effect of neuronally transduced TFEB on the abundance of
endogenous wild-type APP protein and its - and -CTFs in
hippocampi of wild-type mice versus those in GFP-transduced
hippocampi as controls. Remarkably, TFEB transduction led to a
comparable degree of reduction in abundance of total endoge-
nous APP and levels of the- and-CTFs (Fig. 5A,B)mimicking
its effect in APP/PS1 transgenic mice (Fig. 2A,B). This translated
into a 27 and 21% reduction in A40 and A42 species (Fig. 5C),
respectively, indicating that TFEB also alters the metabolism of
wild-type APP protein to reduce A generation.
TFEB expression attenuates A generation, in vitro
To confirm that TFEB expression results in reduced A genera-
tion, we transfected N2a cells stably expressing APP695 with
TFEB or vector control, and examined APP processing. TFEB-
transfected cells demonstrated increased lysosome abundance, as
indicated by upregulation of lysosomal proteins (Figure 6A,B)
driven by eightfold overexpression of TFEB, as we observed pre-
viously in C17.2 cells (Xiao et al., 2014). TFEB-transfected cells
demonstrated a reduction in APP abundance, as well as reduced
levels of - and -CTFs and sAPP in the medium (Fig. 6C,D).
This was not associated with a change in APP transcript (TFEB/
GAPDH) mRNA 1.04 0.04-fold in TFEB transfected vs 1.0
0.01-fold in control, p 0.38, N 3 per group), indicating that
TFEB stimulates increased degradation of APP, which is consis-
tent with the observations in TFEB-transduced hippocampi (Fig.
2). Confocal imaging of a dual fluorescent APP construct (San-
nerud et al., 2011) also demonstrated a qualitative upregulation
of lysosome abundancewith reduction in full-lengthAPPprotein
in TFEB-transfected cells, along with increased localization of
APP in lysosomes (Fig. 6E). Colocalization of full-length APP
(bearing both blue and green fluorescent tags) with LysoTracker
Red-labeled lysosomes (see arrows) was qualitatively observed to
be upregulated in TFEB-expressing cells (Fig. 6E, arrows). This
was associated with reduced A abundance, both intracellularly
(Fig. 7A) and in the medium (Fig. 7B). Importantly, TFEB-
transfected cells demonstrated a reduction in A appearance in
the medium (Fig. 7C,D), indicating that TFEB primarily attenu-
ates A generation, and reduced intracellular A levels are not a
result of increased A secretion.
TFEB accelerates APP flux down the endosome-
lysosome pathway
The intracellular itinerary of APP follows a pathway from the
Golgi (trans-Golgi network), wherein it is post-translationally
Figure 4. Neuronal TFEB transduction reduces amyloid plaque load in APP/PS1 mice. A,
Schematic representation of specific antibodies used in ELISA. B, C, A40 and A42 levels in
dissected hippocampal tissues from AAV8-CMV-FLAG-TFEB (TFEB) and AAV8-CMV-GFP (GFP)-
transduced mice (10 months of age). Tissue was homogenized first in PBS (soluble levels, B),
then in 5 mM guanidine (insoluble levels, C) quantified with ELISA assay. HJ2 and HJ7.4 anti-
bodies were used for capture A40 and A42, respectively, and HJ5.1 antibody was used for
detection. Total A levelswere alsomeasuredwith a combinationofHJ5.1 antibody for capture
and HJ3.5 antibody for detection, as indicated in the schematic. N 8 mice per group; *p
0.05, **p 0.01. D, Representative X-34-stained images from APP/PS1 mice treated as in A.
The area of the hippocampus is outlined with a dotted line. E, F, Quantification of X-34-stained
plaqueburden in thehippocampus (HPC) inmice treatedas inA (E) andplaqueburden stratified
by sex (F ). N  14 (6 male and 8 female) mice per group;*p  0.05, **p  0.01.
4
G, Representative A-immunostained images frommice treated as inB.H, I, Quantification of
A-stained plaque burden in the hippocampus in mice treated as in A (H) and plaque burden
stratified by sex (I).N 14 (6male and 8 female)mice per group; *p 0.05, **p 0.01. HPC,
Hippocampus; CTX, cortex.
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Figure 5. Neuronal TFEB transduction reduces levels of APP, its CTFs, and A species in wild-type mice. A, B, Immunoblot (A) with quantitation (B) of APP, and its- and-CTFs in wild-type
mouse hippocampi transduced with AAV8-CMV-FLAG-TFEB (TFEB) or AAV8-CMV-GFP (GFP) at 8 months of age. N 3 per group; *p 0.05. C, A40 and A42 levels in dissected hippocampal
tissues homogenized in RIPA buffer, frommice transduced as in A. HJ2 and HJ7.4 antibodies were used for capture A40 and A42, respectively, and HJ5.1 antibody was used for detection. N
6 per group; *p 0.05.
Figure 6. TFEB expression increases lysosomes and reduces levels of APP and its cleaved CTFs, in vitro. A, B, Immunoblots (A) with quantification (B) of lysosomal proteins in
N2a-APP695 cells transfected with TFEB or vector control (for 48 h). C, D, Immunoblot (C) with quantitation (D) of APP and its - and -CTFs and of sAPP fragment in the overlying
medium, collected over a duration of 6 h in cells treated as in A. N 3 per group; *p 0.05, **p 0.01. E, N2a cells were transfected with a dual fluorescent APP construct (Sannerud
et al., 2011) with or without the TFEB construct and stained with LysoTracker Red. As shown in these confocal images, colocalization of full-length APP (both blue and green tags) with
LysoTracker Red-labeled lysosomes (see arrows) was qualitatively increased in TFEB-expressing cells (see arrows) compared with empty vector-expressing cells.
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modified after synthesis in the ER, to the plasma membrane
where it can be cleaved via a nonamyloidogenic -cleavage. Al-
ternatively, APP can be endocytosed, and multiple studies have
demonstrated that endocytosis of APP is essential for its colocal-
ization with - and -secretases within endosomes and mul-
tivesicular bodies (formed by trafficking of endosomes into
intraluminal vesicles via sequential activity of endosomal-sorting
complexes required for transport, which are the primary sites for
A generation via amyloidogenic cleavage; Rajendran and Ann-
aert, 2012). Studies have suggested that impairment in endo-
somal flux, likely secondary to lysosome dysfunction, results in
increased transit time within this organelle, which increases the
propensity for - and -cleavage and, hence, A generation
(Cataldo et al., 2000; Rajendran and Annaert, 2012; Morel et al.,
2013; Peric andAnnaert, 2015). Indeed, after endocytosis, studies
have demonstrated that a significant proportion of APP is tar-
geted to the lysosomes (Benowitz et al., 1989; Haass et al., 1992;
Caporaso et al., 1994) and APP levels rapidly build up in the cells
in the presence of lysosomal acidification inhibitors (Golde et al.,
1992), suggesting that lysosomal degradation drives APP prote-
olysis to preclude formation of A peptides (Caporaso et al.,
1992). Given previous reports that TFEB expression can stimu-
late endocytosis ( Pen˜a-Llopis et al., 2011), a potential adverse
consequence of TFEB activation could be increased APP endocy-
tosis resulting in enhanced - and -cleavage and accelerated A
generation, as observed with other experimental manipulations
to stimulate endocytosis (Grbovic et al., 2003; Schneider et al.,
2008; Xiao et al., 2012). Alternatively, TFEB may stimulate flux
through the endosome-lysosome pathway to prevent APP accu-
mulation in endosomes and stimulate its proteolysis in lyso-
somes. To evaluate these possibilities, we examined the effect of
TFEB on APP internalization. N2a-APP95 cells were transfected
with TFEB or vector control, and cell-surface APP was labeled by
biotinylation at 4°C (to prevent endocytosis), followed by re-
warming to stimulate its internalization by endocytosis (Xiao et
al., 2012). At various time points post re-
warming, the cells were treated with
2-mercaptoethanesulfonic acid to remove
cell-surface biotinylated APP molecules,
permitting assessment of kinetics of ap-
pearance and subsequent degradation of
total internalized biotin-tagged APP via
streptavidin capture and immunoblot-
ting. As shown in Figure 8, A and B, cells
transfected with TFEB demonstrated
reduced levels of both surface and inter-
nalized APP, such that the ratio of inter-
nalized to surface APP was not altered
compared with control.
To determine whether the reduced
steady-state levels of APP are due to accel-
erated endocytosis or enhanced flux into
the lysosomes for degradation, we deter-
mined the kinetics of intracellular APP
appearance in this assay (Fig. 8C,D). In-
terestingly, APP was rapidly endocytosed
and the rate of increase of intracellular
APP levels (from T  1 to T  7.5 min)
was not different between TFEB-expre-
ssing cells and controls (Fig. 8C,D). These
data are consistent with a lack of effect of
TFEB on clathrin-mediated endocytosis,
consistent with our previous observations
(Xiao et al., 2014). To determinewhether TFEB expression affects
the kinetics of other transmembrane proteins taken up by
clathrin-mediated endocytosis, we examined the uptake of exog-
enously applied biotin-labeled transferrin. Transferrin binds to the
transferrin receptor and is endocytosed followed by recycling
to the cell surface (Ciechanover et al., 1983). The kinetics of
intracellular appearance of transferrin was not affected by
TFEB expression (Fig. 8E), confirming that TFEB does not
accelerate clathrin-mediated endocytosis.
In contrast, internalized APP levels at 30 min were 32% lower
in TFEB-transfected cells versus 14% lower in control vector-
transfected cells from their respective peak levels at 7.5 min (p
0.017, n 3 experimental trails per group), suggesting that TFEB
accelerates degradation of APP, which is targeted for lysosomal
degradation, in contrast to transferrin that gets recycled to the cell
surface (Ciechanover et al., 1983). Together with the observed
reduction in APP and its various cleaved fragments (Fig. 6C,D)
and attenuated A generation (Fig. 7A–D), these observations
suggest that TFEB expression does not affect APP endocytosis,
but stimulates increased flux of endocytosed APP down the
endosome-lysosome pathway without buildup of APP protein in
intracellular compartments, resulting in its lysosomal degrada-
tion and reduced abundance of APP at steady state.
TFEB enhances lysosomal degradation of APP
To assess the role of lysosomes in APP degradation, we treated
TFEB-transfected (and control) cells with bafilomycin A1 to in-
hibit lysosome acidification and evaluated APP abundance. As
shown in Figure 9A, bafilomycin treatment resulted in increased
APP levels (by 42% compared with control) and largely pre-
vented the TFEB-induced reduction in APP abundance (Fig.
9A,B). This was associated with increase in both - and -CTF
levels (Fig. 9A,C,D) as well as increased generation of A40 (Fig.
9E) and A42 (Fig. 9F), as inhibiting lysosomal degradation of
APP makes it increasingly available as a substrate for processing
Figure7. TFEB expression attenuates Ageneration, in vitro.A,B, Abundance of A40 andA42 species in the cell lysates (A)
andmedium (B) inN2a-APP695 cells transfectedwith TFEB or vector control.C,D, Accumulation of A40 (C) andA42 (D) species
in the overlying medium of cells treated as in A, over the indicated duration. N 5 per group; *p 0.05, **p 0.01.
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via the secretases. We next determined APP half-life by treating
cells with cycloheximide to inhibit protein synthesis and follow
APP abundance. As shown in Figure 9, G and H, TFEB transfec-
tion reduced APP half-life by 42% compared with control indi-
cating enhanced APP degradation. Intriguingly, the levels of
exogenous TFEB also declined rapidly, consistent with the obser-
vations that activated TFEB is degraded rapidly (Roczniak-
Ferguson et al., 2012) possibly via the ubiquitin-proteasome
pathway (Maia et al., 2015). It was also interesting to note that the
abundance of APP in bafilomycin-treated TFEB-expressing cells
was lower than the respective levels in vector controls (Fig. 9B),
again pointing to the reduction in steady-state levels of APP with
TFEB expression, before application of bafilomycin to inhibit
lysosome acidification. Expectedly, this resulted in a relative de-
cline in the CTFs and A peptides in this setting (Fig. 9C–F).
As described previously (Caporaso et al., 1992), inhibition of
lysosome acidification with bafilomycin A1 prolonged APP half-
life, demonstrating that a significant fraction of APP is degraded
via the lysosomes (Fig. 9I–K). Importantly, APP half-life was also
markedly prolonged by 61% in the presence of bafilomycin A1 in
TFEB-transfected cells (Fig. 9L). In summary, these studies dem-
onstrate that TFEB expression accelerates endogenous pathways
for holo-APP degradation via lysosomes, preventing its amy-
loidogenic processing into A.
Discussion
Contemporary approaches to reducingA generation in neurons
have focused upon shifting APP processing to nonamyloidogenic
pathways or sorting APP away from the endosomes where amy-
loidogenic cleavage takes place (Haass et al., 2012). Our study
demonstrates the efficacy of accelerating holo-APP degradation
in lysosomes as a strategy to reduce A generation. Indeed, exog-
enous TFEB expression stimulates lysosome biogenesis in vitro,
reduces full-length APP and its cleaved fragments, attenuates A
generation and release in the medium (Figs. 6, 7), and markedly
shortens APP half-life (Fig. 9) in a lysosome-dependent manner.
These effects are likely secondary to acceleration of lysosomal
degradation of endocytosed APP, as suggested by reduction of
steady-state APP at both the surface and within intracellular
compartments (Fig. 8), and reduced APP half-life with TFEB
expression (Fig. 9). Mirroring these in vitro findings, AAV-
mediated neuronal TFEB transduction in the hippocampus of
Figure 8. TFEB expression reduces steady-state cell-surface and intracellular APP levels without altering its endocytosis. A, B, Immunoblot (A) and quantitation (B) of cell-surface and
internalized APP in N2a-APP695 cells transfectedwith TFEB or vector control, after cell-surface APPwas labeled by biotinylation at 4°C (to prevent endocytosis) followed by rewarming (to 37°C) to
stimulate its internalization by endocytosis (for 10min). Cell-surface APPwas assessed in cells maintained at 4°C. To assess internalized APP, cells were treatedwith 2-mercaptoethanesulfonic acid
to remove cell-surface biotinylated APPmolecules, followed by streptavidin capture and immunoblotting (see Materials andMethods). Inset shows ratio of internalized to surface APP; *p 0.05.
C–E, Immunoblot (C) and quantitation (D) of intracellular APP as a fraction of cell-surface APP to demonstrate kinetics of intracellular A in cells transfected as in A and kinetics of uptake of
biotinylated transferrin [immunoblot (C) with quantitation (E)] in cells treated as in A. N 3 per group. No statistically significant differences were observed by two-way ANOVA.
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APP/PS1 mice also drives upregulation of lysosome abundance
with reduction in APP and its cleaved fragments (Figs. 1, 2). This
translates into reduced steady-state ISF A levels (Fig. 3) and
attenuated amyloid deposits specifically in theAAV-targeted hip-
pocampus (Fig. 4). Remarkably, the magnitude of reduction in
ISF A and amyloid plaque load with neuronal TFEB transduc-
tion compares favorably with that observed with astrocytic TFEB
transduction to accelerate A degradation (Xiao et al., 2014),
Figure 9. TFEB expression enhances lysosomal degradation of APP.A–F, Immunoblot (A)with quantitation of APP (B),-CTF (C),-CTF (D), A40 (E), andA42 (F) in N2a-APP695 cells transfectedwith TFEB or
vectorcontrolandculturedinthepresenceofbafilomycinA1(Baf)ordiluentfor4h.Pvaluesshownarebyposthoctestafterone-wayANOVA.G,N2a-APP695cellsweretransfectedwithTFEBorvectorcontrolandtreatedwith
cycloheximide(CHX;50g/ml)att0.CellswerecollectedattheindicatedtimestoevaluateAPPabundance.H,APPabundanceexpressedasapercentageofbaseline(t0afteradditionofcycloheximide)incellstreated
as inC.N3pergroup. Inset showshalf-lifeofAPP;*p0.05. I,N2a-APP695cellswere transfectedwithTFEBorvector control, andwerepretreatedwithbafilomycinA1ordiluent (100nMfor30min)andtreatedwith
cycloheximide (50g/ml) at t 0. Cells were collected at the indicated times to evaluate APP abundance. J, K, Quantitation of APP abundance at various times in cells treated as in I, in the vector-transfected (J) or
TFEB-transfected(K)groups.N4pergroup.L,Half-lifeofAPPinbafilomycinA1-treatedcellsexpressedasapercentageofdiluent-treatedgroup.N4pergroup;*p0.05.
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highlighting the potential for therapeutic synergy with these dual
approaches.
Our data indicate that lysosomal degradation of APP is an
important component of APP metabolism. Indeed, studies with
pulse-chase radioactive labeling of APP revealed that full-length
APP is degraded with a half-life of	90 min (consistent with our
observations in Fig. 9H), and inhibition of lysosomal acidifica-
tion with chloroquine prolongs its half-life (Caporaso et al.,
1992) and accumulation within lysosomes (Caporaso et al.,
1994). Remarkably, chloroquine treatment resulted in marked
increase in the appearance of A in the medium, providing the
earliest clue on the essential role of lysosomes in facilitating
breakdown of APP. Also, biotinylated cell-surface APP was re-
covered within lysosomes, along with its various CTFs, providing
further evidence that APP and its CTFs are targeted to lysosomes
(Haass et al., 1992). Indeed, BACE1, the rate-limiting step for
amyloidogenic cleavage of APP, and its product, CTF, the pre-
cursor for A, are also degraded within lysosomes (Chen et al.,
2000; Koh et al., 2005), indicating that flux into the lysosomes
may be the critical determinant of whether APPmetabolism leads
to A generation or its nonamyloidogenic degradation.
Endocytosis of APP via clathrin-mediated mechanisms is es-
sential for A generation, and endosomes are the primary sites
for its amyloidogenic processing (Koo and Squazzo, 1994; Perez
et al., 1999; Schneider et al., 2008). Given that endosomal cargo is
typically sorted to other vesicles or targeted to lysosomes for deg-
radation ( The´ry et al., 2002; Hurley, 2008), the mechanisms
whereby APP is channeled toward A generation rather than
lysosomal degradation bear careful examination. Endocytosis is
accelerated with upregulation of endocytotic GTPase effectors,
rab5 and rab7, in vulnerable regions of the brain from individuals
with mild cognitive impairment and AD (Ginsberg et al., 2010)
and gain-of-function polymorphisms in endocytosis pathway
genes confer increased risk forAD (Harold et al., 2009). Concom-
itantly, studies also point to impairment in flux through the
endosome-lysosome pathway (for review, see Peric and Annaert,
2015) resulting in accumulation of endosomes (as observed in
neurons in humans before development of AD pathology;
Cataldo et al., 2000) and in transdifferentiated neurons from pa-
tients’ skin fibroblasts (Israel et al., 2012). Emerging evidence
indicates that lysosome dysfunction may underlie the observed
impairment in endosomal flux (Funk and Kuret, 2012; Peric and
Annaert, 2015). These events permit prolonged colocalization of
APP with the amyloidogenic - and -secretase machinery to
permit A generation (Rajendran and Annaert, 2012). Our find-
ings indicate that activation of TFEB, a transcriptional activator
of multiple lysosomal and trafficking genes (Palmieri et al., 2011;
Settembre et al., 2013a), corrects the underlying lysosomal im-
pairment to stimulate flux through the endosome-lysosome
pathway to enhance APP degradation and reduce A generation.
Our data do not exclude the possibility that TFEB enhances a
pathway for trafficking of APP directly from Golgi to lysosomes,
while bypassing the plasma membrane and endosomes, where
amyloidogenic cleavage of APP takes place. Consistent with this
hypothesis, APP has been demonstrated to interact with sortilin,
aVps10p family receptor, in amanner that increases its lysosomal
targeting and reduces its abundance in lipid rafts, the primary
sites for APP endocytosis (Kojro et al., 2001; Yang et al., 2013)
andwith a related protein, SORLA, which regulates APP localiza-
tion in endosomes and A generation in neurons (Burgert et al.,
2013). It is intriguing to speculate that proteins may regulate
physiologic trafficking of APP to the lysosomes in a manner
mimicking their role in targeting of other lysosomal proteins
(Coutinho et al., 2012; Burgert et al., 2013); further studies will be
required to address this systematically.
TFEB also stimulates autophagy (Settembre et al., 2011), a
lysosomal degradative pathway that is upregulated in advanced
stages of ADpathology (Nixon andYang, 2011). In neurons, both
endosomes and autophagosomes traffic to the lysosomes (Lee et
al., 2011), and accumulation of autophagosomes due to impaired
fusion with lysosomes may also contribute to enhanced A gen-
eration (Yu et al., 2005). A careful examination of neuronal au-
tophagy with modulation of autophagic flux in rat cortical
neurons revealed that while interventions to induce autophago-
some formation did not affect APP metabolism, impairment in
lysosome function increased APP-CTF accumulation with in-
creasedA generation, suggesting that accumulation of autopha-
gosomes rather than upregulation of autophagosome formation
accelerates amyloidogenic APP processing (Boland et al., 2010).
Importantly, TFEB stimulates autophagosome-lysosome fusion
and degradation of autophagosome contents (Settembre et al.,
2011). Therefore, while we did not directly examine the effects of
TFEB activation on neuronal autophagy, our data are also con-
sistent with efficient trafficking of APP into the lysosomes down
this pathway to attenuate A generation.
Recently, AAV-mediated neuronal TFEB activation was not
found to affect amyloid plaque deposition in the 5XFAD mouse
model, whereas TFEB activation was sufficient to drive clearance
of Tau aggregates to attenuate AD pathology (Polito et al., 2014).
Conceivably, the lack of effect of TFEB activation on amyloid
pathology is a function of the rapid development of amyloid
pathology in this model (within a few weeks after birth), com-
pared with the APP/PS1mice where amyloid plaques first appear
at 6 months of age (Yan et al., 2009) or the differences in the level
of TFEB transduction and activation. Indeed, other studies have
demonstrated that inhibition of GSK3 and  isoforms restores
lysosomal acidification with attenuation of A levels and plaque
pathology in the 5XFAD model with increased APP degradation
(Avrahami et al., 2013), likely driven by TFEB activation (Parr et
al., 2012).
It is interesting to note that A half-life was also reduced with
neuronal TFEB expression (Fig. 3A,B). Indeed, neurons also take
up and degrade A, albeit their contribution to A removal from
the ISF is proportionately smaller compared with that of glial cell
types (Kanekiyo and Bu, 2014). TFEB transduction in neurons
may stimulate A uptake by macropinocytosis (Holmes et al.,
2013) as we have previously observed in TFEB-transduced astro-
cytes (Xiao et al., 2014).
Our study highlights the therapeutic potential of neuronal
TFEB activation to reduce A generation and amyloid plaque
pathology.While evidence for endosome-lysosome pathway dys-
function in human AD is predominantly correlative, recent work
demonstrates that A levels in the CSF increase at the time of
initial plaque deposition inAD animalmodels (Maia et al., 2015).
This is followed by a subsequent decline in CSFA, believed to be
from A sequestration by amyloid plaques. A similar decline in
A is also observed preceding the development of dementia in
patientswith dominantly inheritedAD (Fagan et al., 2014). These
findings lend further support to increased A generation as an
early driver of pathology and underscore the potential for target-
ing endosomal-lysosome dysfunction early in AD pathogenesis.
Importantly, we did not observe adverse effects with neuronal
TFEB transduction with the viral gene transfer approach, and no
prior adverse consequences of TFEB expression in CNS cell types
have been described (Tsunemi et al., 2012; Decressac et al., 2013;
Polito et al., 2014; Xiao et al., 2014). Nevertheless, examination of
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the effects of global TFEB activation on neuronal pathology and
cognitive parameters over long-term studies is warranted to fur-
ther assess its therapeutic potential. A strategy of TFEB-mediated
suppression of A generation in neurons is likely to be synergistic
with acceleration of A uptake and degradation by astrocytes
(Xiao et al., 2014) in lowering ISF A levels. In this context,
studies are also needed to determine the effect of exogenous
TFEB on microglial phagocytosis of amyloid material, with its
potential to accelerate removal of amyloid deposits, as a veritable
arm of a multipronged approach to therapeutically target TFEB
activation in multiple CNS cell types in AD.
References
Avrahami L, Farfara D, Shaham-Kol M, Vassar R, Frenkel D, Eldar-
Finkelman H (2013) Inhibition of glycogen synthase kinase-3 amelio-
rates beta-amyloid pathology and restores lysosomal acidification and
mammalian target of rapamycin activity in the Alzheimer disease mouse
model: in vivo and in vitro studies. J Biol Chem 288:1295–1306. CrossRef
Medline
Benowitz LI, Rodriguez W, Paskevich P, Mufson EJ, Schenk D, Neve RL
(1989) The amyloid precursor protein is concentrated in neuronal lyso-
somes in normal and Alzheimer disease subjects. Exp Neurol 106:237–
250. CrossRef Medline
Bero AW, Yan P, Roh JH, Cirrito JR, Stewart FR, Raichle ME, Lee JM, Holtz-
manDM (2011) Neuronal activity regulates the regional vulnerability to
amyloid-beta deposition. Nat Neurosci 14:750–756. CrossRef Medline
BloomGS (2014) Amyloid-beta and tau: the trigger and bullet in Alzheimer
disease pathogenesis. JAMA Neurol 71:505–508. CrossRef Medline
Boland B, SmithDA,MooneyD, Jung SS,WalshDM, Platt FM (2010) Mac-
roautophagy is not directly involved in the metabolism of amyloid pre-
cursor protein. J Biol Chem 285:37415–37426. CrossRef Medline
Burgert T, Schmidt V, Caglayan S, Lin F, Fu¨chtbauer A, Fu¨chtbauer EM,
Nykjaer A, Carlo AS, Willnow TE (2013) SORLA-dependent and -in-
dependent functions for PACS1 in control of amyloidogenic processes.
Mol Cell Biol 33:4308–4320. CrossRef Medline
Callahan MJ, Lipinski WJ, Bian F, Durham RA, Pack A, Walker LC (2001)
Augmented senile plaque load in aged female beta-amyloid precursor
protein-transgenic mice. Am J Pathol 158:1173–1177. CrossRef Medline
Caporaso GL, Gandy SE, Buxbaum JD, Greengard P (1992) Chloroquine
inhibits intracellular degradation but not secretion of Alzheimer beta/A4
amyloid precursor protein. Proc Natl Acad Sci U S A 89:2252–2256.
CrossRef Medline
Caporaso GL, Takei K, Gandy SE, Matteoli M, Mundigl O, Greengard P, De
Camilli P (1994) Morphologic and biochemical analysis of the intracel-
lular trafficking of the Alzheimer beta/A4 amyloid precursor protein.
J Neurosci 14:3122–3138. Medline
Cataldo AM, Peterhoff CM, Troncoso JC, Gomez-Isla T, Hyman BT, Nixon
RA (2000) Endocytic pathway abnormalities precede amyloid beta de-
position in sporadic Alzheimer’s disease and Down syndrome: differen-
tial effects of APOE genotype and presenilin mutations. Am J Pathol
157:277–286. CrossRef Medline
Chen Y, McPhie DL, Hirschberg J, Neve RL (2000) The amyloid precursor
protein-binding protein APP-BP1 drives the cell cycle through the S-M
checkpoint and causes apoptosis in neurons. J Biol Chem275:8929–8935.
CrossRef Medline
Chia PZ, Toh WH, Sharples R, Gasnereau I, Hill AF, Gleeson PA (2013)
Intracellular itinerary of internalised beta-secretase, BACE1, and its po-
tential impact on beta-amyloid peptide biogenesis. Traffic 14:997–1013.
CrossRef Medline
Ciechanover A, Schwartz AL, Dautry-Varsat A, Lodish HF (1983) Kinetics
of internalization and recycling of transferrin and the transferrin receptor
in a human hepatoma cell line. Effect of lysosomotropic agents. J Biol
Chem 258:9681–9689. Medline
Cirrito JR, May PC, O’Dell MA, Taylor JW, Parsadanian M, Cramer JW,
Audia JE, Nissen JS, Bales KR, Paul SM, DeMattos RB, Holtzman DM
(2003) In vivo assessment of brain interstitial fluid with microdialysis
reveals plaque-associated changes in amyloid-beta metabolism and half-
life. J Neurosci 23:8844–8853. Medline
Cirrito JR, Disabato BM, Restivo JL, Verges DK, Goebel WD, Sathyan A,
Hayreh D, D’Angelo G, Benzinger T, Yoon H, Kim J, Morris JC, Mintun
MA, Sheline YI (2011) Serotonin signaling is associated with lower
amyloid-beta levels and plaques in transgenic mice and humans. Proc
Natl Acad Sci U S A 108:14968–14973. CrossRef Medline
Coen K, Flannagan RS, Baron S, Carraro-Lacroix LR, Wang D, Vermeire W,
Michiels C, Munck S, Baert V, Sugita S, Wuytack F, Hiesinger PR, Grin-
stein S, Annaert W (2012) Lysosomal calcium homeostasis defects, not
proton pump defects, cause endo-lysosomal dysfunction in PSEN-
deficient cells. J Cell Biol 198:23–35. CrossRef Medline
Coutinho MF, Prata MJ, Alves S (2012) A shortcut to the lysosome: the
mannose-6-phosphate-independent pathway. Mol Genet Metab 107:
257–266. CrossRef Medline
Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, Casali BT,
Restivo JL, GoebelWD, JamesMJ, BrundenKR,WilsonDA, LandrethGE
(2012) ApoE-directed therapeutics rapidly clear beta-amyloid and re-
verse deficits in AD mouse models. Science 335:1503–1506. CrossRef
Medline
Cruchaga C, Karch CM, Jin SC, Benitez BA, Cai Y, Guerreiro R, Harari O,
Norton J, Budde J, Bertelsen S, Jeng AT, Cooper B, Skorupa T, Carrell D,
Levitch D, Hsu S, Choi J, Ryten M, Ryten M, Hardy J, et al. (2014) Rare
coding variants in the phospholipase D3 gene confer risk for Alzheimer’s
disease. Nature 505:550–554. CrossRef Medline
Cuervo AM, Dice JF (2000) When lysosomes get old. Exp Gerontol 35:119–
131. CrossRef Medline
Decressac M, Mattsson B, Weikop P, Lundblad M, Jakobsson J, Bjo¨rklund A
(2013) TFEB-mediated autophagy rescues midbrain dopamine neurons
from alpha-synuclein toxicity. ProcNatl Acad Sci U S A 110:E1817–1826.
CrossRef Medline
Fagan AM, Xiong C, Jasielec MS, Bateman RJ, Goate AM, Benzinger TL,
Ghetti B, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN,
Salloway S, Schofield PR, Sperling RA,Marcus D, Cairns NJ, Buckles VD,
Ladenson JH, Morris JC,et al. (2014) Longitudinal change in CSF bio-
markers in autosomal-dominant Alzheimer’s disease. Sci Transl Med
6:226ra30. CrossRef Medline
Funk KE, Kuret J (2012) Lysosomal fusion dysfunction as a unifying hy-
pothesis for Alzheimer’s disease pathology. Int J Alzheimers Dis 2012:
752894. CrossRef Medline
Ginsberg SD, Mufson EJ, Counts SE, Wuu J, Alldred MJ, Nixon RA, Che S
(2010) Regional selectivity of rab5 and rab7 protein upregulation inmild
cognitive impairment and Alzheimer’s disease. J Alzheimers Dis 22:631–
639. CrossRef Medline
Golde TE, Estus S, Younkin LH, Selkoe DJ, Younkin SG (1992) Processing
of the amyloid protein precursor to potentially amyloidogenic deriva-
tives. Science 255:728–730. CrossRef Medline
Grbovic OM,Mathews PM, Jiang Y, Schmidt SD, Dinakar R, Summers-Terio
NB, Ceresa BP, Nixon RA, Cataldo AM (2003) Rab5-stimulated up-
regulation of the endocytic pathway increases intracellular beta-cleaved
amyloid precursor protein carboxyl-terminal fragment levels and Abeta
production. J Biol Chem 278:31261–31268. CrossRef Medline
Haass C, Koo EH, Mellon A, Hung AY, Selkoe DJ (1992) Targeting of cell-
surface beta-amyloid precursor protein to lysosomes: alternative process-
ing into amyloid-bearing fragments. Nature 357:500–503. CrossRef
Medline
Haass C, Kaether C, ThinakaranG, Sisodia S (2012) Trafficking and proteo-
lytic processing of APP. Cold Spring Harb Perspect Med 2:a006270.
CrossRef Medline
Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML,
Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C,
Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK,
Brayne C, Rubinsztein DC,et al. (2009) Genome-wide association study
identifies variants at CLU and PICALM associated with Alzheimer’s dis-
ease. Nat Genet 41:1088–1093. CrossRef Medline
Hartmann T, Bieger SC, Bru¨hl B, Tienari PJ, Ida N, Allsop D, Roberts GW,
Masters CL, Dotti CG, Unsicker K, Beyreuther K (1997) Distinct sites of
intracellular production for Alzheimer’s disease A beta40/42 amyloid
peptides. Nat Med 3:1016–1020. CrossRef Medline
Higaki J, Catalano R, Guzzetta AW, Quon D, Nave´ JF, Tarnus C,
D’Orchymont H, Cordell B (1996) Processing of beta-amyloid precur-
sor protein by cathepsin D. J Biol Chem 271:31885–31893. CrossRef
Medline
Holmes BB, DeVos SL, Kfoury N, Li M, Jacks R, Yanamandra K, Ouidja MO,
Brodsky FM, Marasa J, Bagchi DP, Kotzbauer PT, Miller TM, Papy-
Garcia D, Diamond MI (2013) Heparan sulfate proteoglycans mediate
Xiao et al. • Neuronal TFEB Expression Attenuates A Generation J. Neurosci., September 2, 2015 • 35(35):12137–12151 • 12149
internalization and propagation of specific proteopathic seeds. Proc Natl
Acad Sci U S A 110:E3138–3147. CrossRef Medline
Hua Y, Zhao H, Lu X, Kong Y, Jin H (2012) Meta-analysis of the cystatin
C(CST3) geneG73A polymorphism and susceptibility to Alzheimer’s dis-
ease. Int J Neurosci 122:431–438. CrossRef Medline
Hurley JH (2008) ESCRT complexes and the biogenesis of multivesicular
bodies. Curr Opin Cell Biol 20:4–11. CrossRef Medline
IsraelMA, Yuan SH, BardyC, Reyna SM,MuY,Herrera C,HefferanMP,Van
Gorp S, Nazor KL, Boscolo FS, Carson CT, Laurent LC, Marsala M, Gage
FH, Remes AM, Koo EH, Goldstein LS (2012) Probing sporadic and
familial Alzheimer’s disease using induced pluripotent stem cells. Nature
482:216–220. CrossRef Medline
Jankowsky JL, FadaleDJ, Anderson J, XuGM,Gonzales V, JenkinsNA, Cope-
land NG, Lee MK, Younkin LH, Wagner SL, Younkin SG, Borchelt DR
(2004) Mutant presenilins specifically elevate the levels of the 42 residue
beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific
gamma secretase. HumMol Genet 13:159–170. CrossRef Medline
Kamenetz F, Tomita T,HsiehH, SeabrookG, Borchelt D, Iwatsubo T, Sisodia
S, Malinow R (2003) APP processing and synaptic function. Neuron
37:925–937. CrossRef Medline
Kanekiyo T, Bu G (2014) The low-density lipoprotein receptor-related pro-
tein 1 and amyloid-beta clearance in Alzheimer’s disease. Front Aging
Neurosci 6:93. CrossRef Medline
Kanekiyo T, Cirrito JR, Liu CC, Shinohara M, Li J, Schuler DR, Holtzman
DM, Bu G (2013) Neuronal clearance of amyloid-beta by endocytic re-
ceptor LRP1. J Neurosci 33:19276–19283. CrossRef Medline
Kato Y,MaruyamaW,NaoiM,Hashizume Y, Osawa T (1998) Immunohis-
tochemical detection of dityrosine in lipofuscin pigments in the aged
human brain. FEBS Lett 439:231–234. CrossRef Medline
Keilani S, LunY, StevensAC,WilliamsHN, Sjoberg ER,KhannaR,Valenzano
KJ, Checler F, Buxbaum JD, Yanagisawa K, Lockhart DJ, Wustman BA,
Gandy S (2012) Lysosomal dysfunction in a mouse model of Sandhoff
disease leads to accumulation of ganglioside-bound amyloid-beta pep-
tide. J Neurosci 32:5223–5236. CrossRef Medline
Kim J, Castellano JM, Jiang H, Basak JM, Parsadanian M, Pham V, Mason
SM, Paul SM, Holtzman DM (2009) Overexpression of low-density li-
poprotein receptor in the brainmarkedly inhibits amyloid deposition and
increases extracellular A beta clearance. Neuron 64:632–644. CrossRef
Medline
KodamA,MaulikM, Peake K, Amritraj A, Vetrivel KS, Thinakaran G, Vance
JE, Kar S (2010) Altered levels and distribution of amyloid precursor
protein and its processing enzymes in Niemann-Pick type C1-deficient
mouse brains. Glia 58:1267–1281. CrossRef Medline
Koh YH, von Arnim CA, Hyman BT, Tanzi RE, Tesco G (2005) BACE is
degraded via the lysosomal pathway. J Biol Chem 280:32499–32504.
CrossRef Medline
Kojro E, Gimpl G, Lammich S, Marz W, Fahrenholz F (2001) Low choles-
terol stimulates the nonamyloidogenic pathway by its effect on the alpha-
secretase ADAM 10. Proc Natl Acad Sci U S A 98:5815–5820. CrossRef
Medline
Koo EH, Squazzo SL (1994) Evidence that production and release of amy-
loid beta-protein involves the endocytic pathway. J Biol Chem 269:
17386–17389. Medline
Lee CY, Tse W, Smith JD, Landreth GE (2012) Apolipoprotein E promotes
beta-amyloid trafficking and degradation by modulating microglial cho-
lesterol levels. J Biol Chem 287:2032–2044. CrossRef Medline
Lee JH, Yu WH, Kumar A, Lee S, Mohan PS, Peterhoff CM, Wolfe DM,
Martinez-Vicente M, Massey AC, Sovak G, Uchiyama Y, Westaway D,
Cuervo AM, Nixon RA (2010) Lysosomal proteolysis and autophagy
require presenilin 1 and are disrupted by Alzheimer-related PS1 muta-
tions. Cell 141:1146–1158. CrossRef Medline
Lee S, Sato Y, Nixon RA (2011) Lysosomal proteolysis inhibition selectively
disrupts axonal transport of degradative organelles and causes an
Alzheimer’s-like axonal dystrophy. J Neurosci 31:7817–7830. CrossRef
Medline
Ma X, Liu H, Foyil SR, Godar RJ, Weinheimer CJ, Hill JA, Diwan A (2012)
Impaired autophagosome clearance contributes to cardiomyocyte death
in ischemia/reperfusion injury. Circulation 125:3170–3181. CrossRef
Medline
Maia LF, Kaeser SA, Reichwald J, Lambert M, Obermu¨ller U, Schelle J,
Odenthal J, Martus P, Staufenbiel M, Jucker M (2015) Increased CSF
Abeta during the very early phase of cerebral Abeta deposition in mouse
models. EMBOMol Med 7:895–903. CrossRef Medline
Majumdar A, Capetillo-Zarate E, Cruz D, Gouras GK, Maxfield FR (2011)
Degradation of Alzheimer’s amyloid fibrils by microglia requires delivery
of ClC-7 to lysosomes. Mol Biol Cell 22:1664–1676. CrossRef Medline
McBrayerM,NixonRA (2013) Lysosome and calciumdysregulation inAlz-
heimer’s disease: partners in crime. Biochem Soc Trans 41:1495–1502.
CrossRef Medline
Menacherry S, Hubert W, Justice JB Jr (1992) In vivo calibration of micro-
dialysis probes for exogenous compounds. Anal Chem 64:577–583.
CrossRef Medline
Morel E, Chamoun Z, Lasiecka ZM, Chan RB,Williamson RL, Vetanovetz C,
Dall’ArmiC, Simoes S, PointDu JourKS,McCabeBD, Small SA,Di Paolo
G (2013) Phosphatidylinositol-3-phosphate regulates sorting and pro-
cessing of amyloid precursor protein through the endosomal system. Nat
Commun 4:2250. CrossRef Medline
Mueller-Steiner S, Zhou Y, Arai H, Roberson ED, Sun B, Chen J, Wang X, Yu
G, Esposito L, Mucke L, Gan L (2006) Antiamyloidogenic and neuro-
protective functions of cathepsin B: implications for Alzheimer’s disease.
Neuron 51:703–714. CrossRef Medline
NeelyKM,GreenKN, LaFerla FM (2011) Presenilin is necessary for efficient
proteolysis through the autophagy-lysosome system in a gamma-
secretase-independent manner. J Neurosci 31:2781–2791. CrossRef
Medline
Nixon RA, Yang DS (2011) Autophagy failure in Alzheimer’s disease—
locating the primary defect. Neurobiol Dis 43:38–45. CrossRef Medline
Palmieri M, Impey S, Kang H, di Ronza A, Pelz C, Sardiello M, Ballabio A
(2011) Characterization of the CLEAR network reveals an integrated
control of cellular clearance pathways. Hum Mol Genet 20:3852–3866.
CrossRef Medline
Parr C, Carzaniga R, Gentleman SM, Van Leuven F, Walter J, Sastre M
(2012) Glycogen synthase kinase 3 inhibition promotes lysosomal bio-
genesis and autophagic degradation of the amyloid-beta precursor pro-
tein. Mol Cell Biol 32:4410–4418. CrossRef Medline
Pen˜a-Llopis S, Vega-Rubin-de-Celis S, Schwartz JC,Wolff NC, Tran TA, Zou
L, Xie XJ, Corey DR, Brugarolas J (2011) Regulation of TFEB and
V-ATPases by mTORC1. EMBO J 30:3242–3258. CrossRef Medline
Perez RG, Soriano S, Hayes JD, Ostaszewski B, Xia W, Selkoe DJ, Chen X,
Stokin GB, Koo EH (1999) Mutagenesis identifies new signals for beta-
amyloid precursor protein endocytosis, turnover, and the generation of
secreted fragments, including Abeta42. J Biol Chem 274:18851–18856.
CrossRef Medline
Peric A, AnnaertW (2015) Early etiology of Alzheimer’s disease: tipping the
balance toward autophagy or endosomal dysfunction? Acta Neuropathol
129:363–381. CrossRef Medline
Polito VA, Li H, Martini-Stoica H, Wang B, Yang L, Xu Y, Swartzlander DB,
Palmieri M, di Ronza A, Lee VM, Sardiello M, Ballabio A, Zheng H
(2014) Selective clearance of aberrant tau proteins and rescue of neuro-
toxicity by transcription factor EB. EMBO Mol Med 6:1142–1160.
CrossRef Medline
Rajendran L, Annaert W (2012) Membrane trafficking pathways in Alzhei-
mer’s disease. Traffic 13:759–770. CrossRef Medline
Roczniak-Ferguson A, Petit CS, Froehlich F, Qian S, Ky J, Angarola B,
Walther TC, Ferguson SM (2012) The transcription factor TFEB links
mTORC1 signaling to transcriptional control of lysosome homeostasis.
Sci Signal 5:ra42. CrossRef Medline
Roh JH, Huang Y, Bero AW, Kasten T, Stewart FR, Bateman RJ, Holtzman
DM (2012) Disruption of the sleep-wake cycle and diurnal fluctuation
of beta-amyloid in mice with Alzheimer’s disease pathology. Sci Transl
Med 4:150ra122. CrossRef Medline
Sannerud R, Declerck I, Peric A, Raemaekers T, Menendez G, Zhou L, Veerle
B, Coen K,Munck S, De Strooper B, Schiavo G, AnnaertW (2011) ADP
ribosylation factor 6 (ARF6) controls amyloid precursor protein (APP)
processing bymediating the endosomal sorting of BACE1. ProcNatl Acad
Sci U S A 108:E559–568. CrossRef Medline
SardielloM, Palmieri M, di Ronza A,Medina DL, ValenzaM, Gennarino VA,
Di Malta C, Donaudy F, Embrione V, Polishchuk RS, Banfi S, Parenti G,
Cattaneo E, Ballabio A (2009) A gene network regulating lysosomal bio-
genesis and function. Science 325:473–477. CrossRef Medline
Schneider A, Rajendran L, HonshoM, Gralle M, Donnert G,Wouters F, Hell
SW, Simons M (2008) Flotillin-dependent clustering of the amyloid
12150 • J. Neurosci., September 2, 2015 • 35(35):12137–12151 Xiao et al. • Neuronal TFEB Expression Attenuates A Generation
precursor protein regulates its endocytosis and amyloidogenic processing
in neurons. J Neurosci 28:2874–2882. CrossRef Medline
Schuur M, Ikram MA, van Swieten JC, Isaacs A, Vergeer-Drop JM, Hofman
A, Oostra BA, Breteler MM, van Duijn CM (2011) Cathepsin D gene
and the risk of Alzheimer’s disease: a population-based study and meta-
analysis. Neurobiol Aging 32:1607–1614. CrossRef Medline
Settembre C, Di Malta C, Polito VA, Garcia Arencibia M, Vetrini F, Erdin S,
Erdin SU, Huynh T, Medina D, Colella P, Sardiello M, Rubinsztein DC,
Ballabio A (2011) TFEB links autophagy to lysosomal biogenesis. Sci-
ence 332:1429–1433. CrossRef Medline
Settembre C, Fraldi A, Medina DL, Ballabio A (2013a) Signals from the
lysosome: a control centre for cellular clearance and energy metabolism.
Nat Rev Mol Cell Biol 14:283–296. CrossRef Medline
Settembre C, De Cegli R, Mansueto G, Saha PK, Vetrini F, Visvikis O, Huynh
T, Carissimo A, Palmer D, Klisch TJ, Wollenberg AC, Di Bernardo D,
Chan L, Irazoqui JE, Ballabio A (2013b) TFEB controls cellular lipid
metabolism through a starvation-induced autoregulatory loop. Nat Cell
Biol 15:647–658. CrossRef Medline
Sheline YI,West T, Yarasheski K, SwarmR, JasielecMS, Fisher JR, FickerWD,
Yan P, XiongC, FrederiksenC, GrzelakMV, Chott R, BatemanRJ,Morris
JC, Mintun MA, Lee JM, Cirrito JR (2014) An antidepressant decreases
CSF Abeta production in healthy individuals and in transgenic AD mice.
Sci Transl Med 6:236re4. CrossRef Medline
Tamboli IY, Hampel H, Tien NT, Tolksdorf K, Breiden B, Mathews PM,
Saftig P, Sandhoff K, Walter J (2011) Sphingolipid storage affects au-
tophagic metabolism of the amyloid precursor protein and promotes
Abeta generation. J Neurosci 31:1837–1849. CrossRef Medline
The´ry C, Zitvogel L, Amigorena S (2002) Exosomes: composition, biogen-
esis and function. Nat Rev Immunol 2:569–579. Medline
Tsunemi T, Ashe TD,Morrison BE, Soriano KR, Au J, Roque RA, Lazarowski
ER, Damian VA, Masliah E, La Spada AR (2012) PGC-1alpha rescues
Huntington’s disease proteotoxicity by preventing oxidative stress and
promoting TFEB function. Sci Transl Med 4:142ra97. CrossRef Medline
West MJ, Slomianka L, Gundersen HJ (1991) Unbiased stereological esti-
mation of the total number of neurons in the subdivisions of the rat
hippocampus using the optical fractionator. Anat Rec 231:482–497.
CrossRef Medline
Wolfe DM, Lee JH, Kumar A, Lee S, Orenstein SJ, Nixon RA (2013) Au-
tophagy failure in Alzheimer’s disease and the role of defective lysosomal
acidification. Eur J Neurosci 37:1949–1961. CrossRef Medline
Wyss-Coray T, Loike JD, Brionne TC, Lu E, Anankov R, Yan F, Silverstein SC,
Husemann J (2003) Adult mouse astrocytes degrade amyloid-beta in
vitro and in situ. Nat Med 9:453–457. CrossRef Medline
XiaoQ, Gil SC, Yan P,Wang Y,Han S, Gonzales E, Perez R, Cirrito JR, Lee JM
(2012) Role of phosphatidylinositol clathrin assembly lymphoid-
myeloid leukemia (PICALM) in intracellular amyloid precursor protein
(APP) processing and amyloid plaque pathogenesis. J Biol Chem 287:
21279–21289. CrossRef Medline
XiaoQ, Yan P,MaX, LiuH, Perez R, ZhuA,Gonzales E, Burchett JM, Schuler
DR, Cirrito JR, Diwan A, Lee JM (2014) Enhancing astrocytic lysosome
biogenesis facilitates Abeta clearance and attenuates amyloid plaque
pathogenesis. J Neurosci 34:9607–9620. CrossRef Medline
Yan P, Bero AW, Cirrito JR, Xiao Q, Hu X, Wang Y, Gonzales E, Holtzman
DM, Lee JM (2009) Characterizing the appearance and growth of amy-
loid plaques in APP/PS1 mice. J Neurosci 29:10706–10714. CrossRef
Medline
Yang M, Virassamy B, Vijayaraj SL, Lim Y, Saadipour K, Wang YJ, Han YC,
Zhong JH, Morales CR, Zhou XF (2013) The intracellular domain of
sortilin interacts with amyloid precursor protein and regulates its lyso-
somal and lipid raft trafficking. PLoS One 8:e63049. CrossRef Medline
Yu WH, Cuervo AM, Kumar A, Peterhoff CM, Schmidt SD, Lee JH, Mohan
PS, Mercken M, Farmery MR, Tjernberg LO, Jiang Y, Duff K, Uchiyama
Y, Na¨slund J, Mathews PM, Cataldo AM, Nixon RA (2005) Macroau-
tophagy—a novel Beta-amyloid peptide-generating pathway activated in
Alzheimer’s disease. J Cell Biol 171:87–98. CrossRef Medline
Xiao et al. • Neuronal TFEB Expression Attenuates A Generation J. Neurosci., September 2, 2015 • 35(35):12137–12151 • 12151
